An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: Bladder hotspot dose and prostate size are significant predictors

Radiotherapy and Oncology

Volumn 88, Issue 1, 2008, Pages 108-114

  Steggerda, Marcel J ^a   van der Poel, Henk G ^b   Moonen, Luc M F ^a  

^a Department of Radiation Oncology ^*

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Bladder dose; Prostate brachytherapy; Prostate volume; Urinary morbidity

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; IMPLANTATION; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION;

BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATE; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOGRAPHY, INTERVENTIONAL; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; ULTRASONOGRAPHY, INTERVENTIONAL; URINARY BLADDER; URINATION DISORDERS;

EID: 46049085024     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.10.030     Document Type: Article

References (31)

1. Bottomley D., Ash D., Al-Qaisieh B., et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 82 (2007) 46-49
2. Caffo O., Fellin G., Bolner A., et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 31-37
3. 125Iodine prostate brachythrapy in the U.K. A prospective study. Clin Oncol 16 (2004) 95-104
4. Sherertz T., Wallner K., Wang H., Sutlief S., and Russel K. Long-term urinary function after transperineal brachytherapy for patients with large prostate glands. Int J Radiat Oncol Biol Phys 51 (2001) 1241-1245
5. Wust P., von Borczyskowski D.W., Henkel T., et al. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiother Oncol 73 (2004) 39-48
6. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 62 (2005) 981-987
7. Salem N., Simonian-Sauve M., Rosello R., Alzieu C., Gravis G., Maraninchi D., et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localised prostate cancer: a phase 2 study. Radiother Oncol 66 (2003) 159-165
8. Van Gellekom M.P.R., Moerland M.A., van Vulpen M., Wijrdeman H.K., and Battermann J.J. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry. Int J Radiat Oncol Biol Phys 63 (2005) 772-780
9. 125iodine transperineal prostate brachytherapy. Radiother Oncol 73 (2004) 33-38
10. Cesaretti J.A., Stone N.N., and Stock R.G. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 1085-1092
11. Akimoto T., Katoh H., Noda S., et al. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: second analysis to determine the correlation between urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity. Int J Radiat Oncol Biol Phys 63 (2005) 472-478
12. Chen A.B., D'Amico A.V., Neville B.A., and Earle C.C. Patient and treatment factors associated with complications after prostate brachythrapy. J Clin Oncol 24 (2006) 5298-5304
13. Merrick G.S., Wallner K.E., and Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology 62 (2003) 786-792
14. Niehaus B.S., Merrick G.S., Butler W.M., et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 64 (2006) 136-143
15. Pinkawa M., Fischedick K., Piroth M.D., et al. Health-related quality of life after permanent interstitial brachytherapy for prostate cancer; correlation with postimplant CT scan parameters. Strahlenther Onkol 182 (2006) 660-665
16. Thomas M.D., Cormack R., Tempany C.M., et al. Identifying the predictors of acute urinary retention following magnetic-resonance-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 47 (2000) 905-908
17. Merrick G.S., Butler W.M., Wallner K.E., Galbreath R.W., and Lief J.H. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 56 (2003) 454-461
18. 125Iodine prostate brachytherapy. Clin Oncol 18 (2006) 326-332
19. Martin A.G., Roy J., Beaulieu L., Pouliot J., Harel F., and Vigneault E. Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: a 12-year Canadian experience. Int J Radiat Oncol Biol Phys 67 (2007) 334-341
20. Barry M.J., Fowler F.J., and O'Leary M.P. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148 (1992) 1549-1557
21. Steggerda M., Schneider C., van Herk M., Zijp L., Moonen L., and van der Poel H. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants. Med Phys 32 (2005) 2262-2270
22. Steggerda M.J., Moonen L.M.F., van der Poel H.G., and Schneider C.J. The influence of geometrical changes on the dose distribution after I-125 seed implantation of the prostate. Radiother Oncol 83 (2007) 11-17
23. Pinkawa M., Asadpour B., Siluschek J., et al. Bladder extension variability during pelvic external beam radiotherapy with a full or empty bladder. Radiother Oncol 83 (2007) 163-167
24. Salembier C., Lavagnini P., Nickers P., et al. Tumour and target volumes in permanent prostate brachythrapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachythrapy. Radiother Oncol 83 (2007) 3-10
25. Cheung R.M., Tucker S.L., Dong L., et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67 (2007) 1059-1065
26. Hinerman-Mulroy A., Merrick G.S., Butler W.M., Wallner K.E., Allan Z., and Adamovich E. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367-1382
27. Buskirk S.J., Pinkstaff D.M., Petrou S.P., et al. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys 59 (2004) 1360-1366
28. Eapen L., Kayser C., Deshaies Y., et al. Correlating the degree of needle trauma during prostate brachytherapy and the development of acute urinary toxicity. Int J Radiat Oncol Biol Phys 59 (2004) 1392-1394
29. Merrick G.S., Butler W.M., Galbreath R.W., Lief J.H., and Donzella J.G. Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy. Urology 57 (2001) 524-529
30. Crook J., McLean M., Catton C., Yeung I., Tsihlias J., and Pintilie M. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
31. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: implications for treatment planning. Int J Radiat Oncol Biol Phys 63 (2005) 479-491